Pharmaceuticals

Suvoda's latest platform release creates a global experience across study data, patient engagement, scheduling, payments, and clinical trial operations

CONSHOHOCKEN, Pa., Sept. 30, 2026 /PRNewswire/ -- Suvoda , a global clinical trial technology company, today announced a new release of important advancements since unifying the marke...

2026-09-30 22:00 2659

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

* Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. * The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in Lexington, Kentucky. * This partnership addresse...

2026-09-30 21:54 1835

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC

First clinical program built on Phrontline's DLP1 branched dual-payload linker platform HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), today announced that the f...

2026-09-30 21:53 2083

The 94th CMEF, the World's Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24

BEIJING, Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Hea...

2026-09-30 21:16 1457

Yuyu Pharma Brings Ari's Purrfect to Amazon Accelerate 2026

Korean pharmaceutical company explores Amazon AI and seller tools to grow its U.S. feline-health brand SEOUL, South Korea, Sept. 30, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma (KRX: 000220), attended Amazon Accelerate 2026 in Seattle from September 22 to 24 to explore how Amazon'...

2026-09-30 21:00 1316

Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China

BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatmen...

2026-09-30 20:00 1296

Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China

BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatmen...

2026-09-30 20:00 1341

EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity

HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announced that its Phase 1b randomized, double-blind, placebo-controlled study of ecnoglutide, the worl...

2026-09-30 19:00 2725

Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma

SEONGNAM, South Korea, Sept. 30, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the Orpha...

2026-09-30 17:33 1087

Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become th...

2026-09-30 13:57 1227

Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access

New Rare Cancer Centre brings together expertise in rare and complex cancers, giving patients, families and referring physicians a single point of access to specialist care. SINGAPORE, Sept. 30, 2026 /PRNewswire/ -- Marking Rare Cancer Day, Tamarind Health today announced the launch of its Rare ...

2026-09-30 13:28 1564

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

* FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. * The designation recognizes the program's potential to address an important unmet need by enabling an imaging-first approach to ...

2026-09-30 08:26 1602

Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility

* Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. * With its investment through the Life Sciences Scale-Up Fund, the Ontario government is supporting healthcare innovation and reinforcing its province's leadership p...

2026-09-30 03:28 2981

Yuyu Teijin Medicare Uses Drones to Deliver Medical Supplies to Patients on Korea's Remote Islands

SEOUL, South Korea, Sept. 29, 2026 /PRNewswire/ -- Yuyu Teijin Medicare, a home healthcare joint venture between Yuyu Pharma of Korea and Teijin Pharma of Japan, has completed a pilot delivery of medical supplies by drone to a ventilator patient living on a remote Korean island. In the test, a d...

2026-09-29 21:00 2085

iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. CHENGDU, China, Sept. 29, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemical...

2026-09-29 13:41 1941

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

* HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing           * Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharm...

2026-09-29 13:12 2126

Vitaceuticals Founders Win National Manufacturing Award for Australian-Made Health Range

Pharmacists Sally Tadros and Cyndi Khawaja recognised at the 2026 Australian Women's Small Business Champion Awards. SYDNEY, Sept. 29, 2026 /PRNewswire/ -- Sydney pharmacists and sisters Sally Tadros and Cyndi Khawaja have won the Manufacturing category at the 2026 Australian Women's Small Busin...

2026-09-29 09:16 1057

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-wee...

2026-09-29 08:00 2293

Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million

– LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center – – Jie D'Elia, Ph.D., joins as Chief Executive Officer and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer; c...

2026-09-28 18:59 2568

Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabol...

2026-09-28 18:30 2326
123456 ... 349